Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Corporate Tax Law To Change Medical Industry Landscape

This article was originally published in PharmAsia News

Executive Summary

China's new corporate income tax law, which came into effect in 2008, seeks to lower corporate income tax for companies that qualify as high-tech enterprises. To encourage more technology investment, corporate R&D expenses will receive 150 percent deduction before taxation. Revenue from the commercialization or transfer of technology will be tax-exempted for the first 5 million yuan, with taxation halved for the balance. To remove the difference in taxation for local and foreign firms, now at 33 percent and 18 percent respectively, the new law will standardize the rate at 25 percent. Foreign pharmaceutical companies will be taxed 18 percent this year, 20 percent in 2009, 22 percent in 2010, 24 percent in 2011, and 25 percent from 2012. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel